# Targeting Cancer Metabolism With Ketogenic Therapy and Fasting

Page: https://stenobird.com/podcast/metabolic-mind-6253550/targeting-cancer-metabolism-with-ketogenic-therapy-and-fasting
Text version: https://stenobird.com/podcast/metabolic-mind-6253550/targeting-cancer-metabolism-with-ketogenic-therapy-and-fasting.md
Podcast: [Metabolic Mind](https://stenobird.com/podcast/metabolic-mind-6253550)
Published: 2026-08-04T12:00:00+00:00
Episode link: https://metabolicmind.org/
Audio file: https://episodes.captivate.fm/episode/266f044b-9063-436e-8290-a4a02bf4ca5a.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/metabolic-mind-6253550/episodes/targeting-cancer-metabolism-with-ketogenic-therapy-and-fasting
Duration seconds: 2206

## Resource

Could metabolic therapies become part of the future of cancer care? That question sits at the center of Dr. Bret Scher’s conversation with neurologist and researcher Dr. Matthew Phillips, whose recent study explored a metabolic approach in people with glioblastoma, one of the most aggressive forms of brain cancer. Rather than relying on a single intervention, the study combined a ketogenic diet, intermittent fasting, and repeated five-day fasts alongside standard chemotherapy and radiation. Together, these strategies were designed to lower the Glucose Ketone Index, or GKI, by reducing glucose and increasing ketones. In this conversation, they explore: Why cancer cell metabolism is becoming an important area of research How glucose, ketones, and mitochondrial function may influence cancer growth Why the GKI was a central target in the study How fasting and ketogenic therapy were integrated with standard cancer treatment The difference between intentional weight loss and cancer cachexia Why quality of life deserves as much attention as survival What the study’s long-term survivors may teach researchers Why larger randomized trials are still needed Participants following the metabolic protocol achieved an average GKI of 1.88, and every participant completed all eight five-day fasts. The metabolic therapy group also had a median survival of 21 months compared with 14 months in the control group, along with a higher rate of survival beyond three years. These results offer a compelling reason to keep studying this approach, particularly in a cancer with such limited treatment options and a difficult prognosis. Since the trial was small and nonrandomized, it can’t provide definitive answers, but it does give researchers a strong foundation to build on. 👉 Want to stay up to da…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/metabolic-mind-6253550/episodes/targeting-cancer-metabolism-with-ketogenic-therapy-and-fasting/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/metabolic-mind-6253550/targeting-cancer-metabolism-with-ketogenic-therapy-and-fasting.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.